Robert C. Stein

9.3k total citations · 1 hit paper
110 papers, 5.7k citations indexed

About

Robert C. Stein is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Robert C. Stein has authored 110 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 26 papers in Oncology and 25 papers in Cancer Research. Recurrent topics in Robert C. Stein's work include Breast Cancer Treatment Studies (20 papers), Estrogen and related hormone effects (16 papers) and Protein Kinase Regulation and GTPase Signaling (11 papers). Robert C. Stein is often cited by papers focused on Breast Cancer Treatment Studies (20 papers), Estrogen and related hormone effects (16 papers) and Protein Kinase Regulation and GTPase Signaling (11 papers). Robert C. Stein collaborates with scholars based in United Kingdom, Canada and Germany. Robert C. Stein's co-authors include Michael D. Waterfield, R. Charles Coombes, Marketa Zvelebil, Stefano Volinia, Mitch Dowsett, Bart Vanhaesebroeck, M O'hare, A J Hedley, Julian Downward and Lindsay K. MacDougall and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Robert C. Stein

105 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

2009 504 citations Gϋnter von Minckwitz, Marcus Schmidt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert C. Stein United Kingdom	39	2.5k	1.7k	856	829	819	110	5.7k
Mark A. Watson United States	48	3.4k 1.4×	1.9k 1.1×	1.4k 1.7×	794 1.0×	1.7k 2.1×	129	7.2k
Daniel E. Gómez Argentina	37	2.6k 1.1×	1.4k 0.8×	510 0.6×	372 0.4×	1.9k 2.3×	130	5.9k
Biaoyang Lin United States	47	5.4k 2.2×	919 0.5×	946 1.1×	693 0.8×	1.4k 1.7×	121	8.0k
Joseph Locker United States	50	3.6k 1.5×	3.0k 1.7×	473 0.6×	754 0.9×	654 0.8×	176	8.4k
Anne‐Marie Mes‐Masson Canada	50	4.4k 1.8×	2.7k 1.6×	1.2k 1.4×	975 1.2×	1.9k 2.4×	272	9.1k
Stefania Staibano Italy	43	2.8k 1.1×	2.4k 1.4×	1.2k 1.4×	471 0.6×	689 0.8×	229	6.5k
Éva Szabó United States	43	4.2k 1.7×	2.2k 1.3×	1.2k 1.4×	590 0.7×	1.4k 1.8×	199	8.1k
Anthony D. Whetton United Kingdom	52	5.2k 2.1×	1.4k 0.8×	540 0.6×	460 0.6×	1.0k 1.2×	277	8.9k
Nicolás André France	50	4.1k 1.6×	2.8k 1.6×	1.2k 1.4×	434 0.5×	1.8k 2.2×	264	8.6k
Wolfgang Tilgen Germany	50	2.9k 1.2×	3.2k 1.9×	606 0.7×	623 0.8×	685 0.8×	264	8.4k

Countries citing papers authored by Robert C. Stein

Since Specialization

Citations

This map shows the geographic impact of Robert C. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Stein more than expected).

Fields of papers citing papers by Robert C. Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert C. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Stein. The network helps show where Robert C. Stein may publish in the future.

Co-authorship network of co-authors of Robert C. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Robert C. Stein. A scholar is included among the top collaborators of Robert C. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert C. Stein. Robert C. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stein, Robert C., A. Marshall, Luke Hughes‐Davies, et al.. (2025). 190O Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-Parameter Analysis) feasibility study. ESMO Open. 10. 104744–104744. 1 indexed citations

Elliott, Daisy, Marcus Jepson, Bridget Young, et al.. (2024). The role of healthcare professionals’ communication in trial participation decisions: a qualitative investigation of recruitment consultations and patient interviews across three RCTs. Trials. 25(1). 829–829.

Bentham, Robert B., Emily T.Y. Tong, Clement Lo, et al.. (2024). Multistate Gene Cluster Switches Determine the Adaptive Mitochondrial and Metabolic Landscape of Breast Cancer. Cancer Research. 84(17). 2911–2925. 1 indexed citations

Smith, Teresa, Sarah Anne J. Guagliardo, Allison Taylor Walker, et al.. (2023). Effect of Predeparture Testing on Postarrival SARS-CoV-2–Positive Test Results Among International Travelers — CDC Traveler-Based Genomic Surveillance Program, Four U.S. Airports, March–September 2022. MMWR Morbidity and Mortality Weekly Report. 72(8). 206–209. 9 indexed citations

Bartlett, John M.S., Jane Bayani, Andrea Marshall, et al.. (2016). Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. JNCI Journal of the National Cancer Institute. 108(9). djw050–djw050. 148 indexed citations

Bartlett, John M.S., Daniel Rea, Sarah E. Pinder, et al.. (2016). Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. European Journal of Surgical Oncology. 42(7). 994–998. 4 indexed citations

Stein, Robert C., Janet Dunn, John M.S. Bartlett, et al.. (2016). OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment. 20(10). 1–202. 55 indexed citations

Schmid, Peter, Duncan Wheatley, Richard D. Baird, et al.. (2016). Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603). Cancer Research. 76(4_Supplement). OT1–3. 4 indexed citations

Ercole, Cesar J., Tracy L. Krebs, Ryan K. Berglund, et al.. (2014). MP58-19 PATIENT-REPORTED HEALTH RELATED QUALITY-OF-LIFE (HRQOL) OUTCOMES OF PATIENTS ON ACTIVE SURVEILLANCE: RESULTS OF A PROSPECTIVE, LONGITUDINAL, SINGLE-CENTER STUDY. The Journal of Urology. 191(4S). 1 indexed citations

10.

Thiede, Bernd, Christian Koehler, Margarita Strozynski, et al.. (2012). High Resolution Quantitative Proteomics of HeLa Cells Protein Species Using Stable Isotope Labeling with Amino Acids in Cell Culture(SILAC), Two-Dimensional Gel Electrophoresis(2DE) and Nano-Liquid Chromatograpohy Coupled to an LTQ-OrbitrapMass Spectrometer. Molecular & Cellular Proteomics. 12(2). 529–538. 98 indexed citations

11.

Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281. 141 indexed citations

12.

Schmid, Monika, Ursula Zimny‐Arndt, John C. Rohloff, et al.. (2011). Quantitative phosphoproteomics reveals link between Helicobacter pylori infection and RNA splicing modulation in host cells. PROTEOMICS. 11(14). 2798–2811. 30 indexed citations

13.

Stein, Robert C., et al.. (2004). Three-dimensional in vitro tissue culture models of breast cancer — a review. Breast Cancer Research and Treatment. 85(3). 281–291. 244 indexed citations

14.

Stein, Robert C. & Marketa Zvelebil. (2002). The Application of 2D Gel-Based Proteomics Methods to the Study of Breast Cancer. Journal of Mammary Gland Biology and Neoplasia. 7(4). 385–393. 21 indexed citations

15.

Stein, Robert C. & Michael D. Waterfield. (2000). PI3-kinase inhibition: a target for drug development?. Molecular Medicine Today. 6(9). 347–358. 165 indexed citations

16.

Siegal, Gregg, Ben Davis, Søren M. Kristensen, et al.. (1998). Solution structure of the C-terminal SH2 domain of the p85α regulatory subunit of phosphoinositide 3-kinase 1 1Edited by P. E. Wright. Journal of Molecular Biology. 276(2). 461–478. 48 indexed citations

17.

Zvelebil, Marketa, Lindsay K. MacDougall, Sally J. Leevers, et al.. (1996). Structural and functional diversity of phosphoinositide 3-kinases. Philosophical Transactions of the Royal Society B Biological Sciences. 351(1336). 217–223. 86 indexed citations

18.

Bower, Mark, et al.. (1991). The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy. Cancer Chemotherapy and Pharmacology. 28(4). 311–312. 11 indexed citations

19.

Stein, Robert C., S. R. Cannon, A.M. Cassoni, et al.. (1991). Clinical oncology: Case presentations from oncology centres 1. Ewing's sarcoma. European Journal of Cancer and Clinical Oncology. 27(11). 1525–1533. 2 indexed citations

20.

Stein, Robert C., Mitch Dowsett, David Cunningham, et al.. (1990). Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. British Journal of Cancer. 61(3). 451–453. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact